Evotec: Putting Its Money on Services
This article was originally published in Start Up
Executive Summary
Evotec BioSystems AG's all-share acquisition of Oxford Asymmetry International PLC is, most apparently, part of a recent trend among German biotechs to take advantage of their relatively high valuations to grow by acquisition. But the deal, between two service companies, also appears to challenge a widespread view amongst platform companies that in order to build a sustainable business you need your own products.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?